Vertex Pharmaceuticals (VRTX) closed at $489.43 in the latest trading session, marking a +0.84% move from the prior day. This move outpaced the S&P 500's daily gain of 0.13%. At the same time, the Dow ...

both Vertex Pharmaceuticals Incorporated and Regeneron Pharmaceuticals Inc have a grade of A. For investors who focus solely on a company’s upward growth, further research should be conducted into ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $508.38, a high estimate of ...

In a report released today, Brian Abrahams from RBC Capital maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report), ...

Vertex Pharmaceuticals Inc. closed $45.72 below its 52-week high ($510.64), which the company achieved on August 1st.

The stock's fall snapped a four-day winning streak.

According to Benzinga Pro, Vertex Pharmaceuticals's peer group average for short interest as a percentage of float is 6.15%, ...

And we're really excited to have the Vertex IR team with us ... billion to $10.85 billion in total product revenues, that's 9% growth at the midpoint. So continued strong performance in CF.